A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder

Brazilian Journal of Medical and Biological Research

Volumn 41, Issue 3, 2008, Pages 250-257

  Szobot, C M ^a,b   Rohde, L A ^a   Katz, B ^a   Ruaro, P ^a,b   Schaefer, T ^a,b   Walcher, M ^a,b   Bukstein, O ^c   Pechansky, F ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adolescents; Attention deficit hyperactivity disorder; Methylphenidate; Substance use disorder; Treatment

Indexed keywords

CANNABIS; COCAINE; METHYLPHENIDATE; PLACEBO;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CANNABIS ADDICTION; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL STUDY; CLINICAL TRIAL; COCAINE DEPENDENCE; COMORBIDITY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DECREASED APPETITE; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; DRUG USE; HUMAN; MALE; OUTCOME ASSESSMENT; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SUBSTANCE ABUSE; TREATMENT DURATION;

CANNABIS SATIVA;

EID: 44449128046     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2008005000011     Document Type: Article

References (40)

1. Bukstein OG, Bernet W, Arnold V, Beitchman J, Shaw J, Benson RS, et al. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry 2005; 44: 609-621.
2. Galduroz JC, Noto AR, Nappo SA, Carlini EA. Household survey on drug abuse in Brazil: study involving the 107 major cities of the country - 2001. Addict Behav 2005; 30: 545-556.
3. WHO. World Health Organization. http://www.who.int/substance_abuse/ facts/cannabis/en/index.html. Accessed January 8, 2006.
4. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164: 942-948.
5. Rohde LA, Biederman J, Busnello EA, Zimmermann H, Schmitz M, Martins S, et al. ADHD in a school sample of Brazilian adolescents: a study of prevalence, comorbid conditions, and impairments. J Am Acad Child Adolesc Psychiatry 1999; 38: 716-722.
6. Rohde LA. ADHD in Brazil: the DSM-IV criteria in a culturally different population. J Am Acad Child Adolesc Psychiatry 2002; 41: 1131-1133.
7. Lesesne C, Abramowitz A, Perou R, Brann E. Attention deficit/ hyperactivity disorder: A public health research agenda. http://www.cdc.gov/ncbddd/adhd/dadphra.htm. Accessed January 8, 2006.
8. Horner BR, Scheibe KE. Prevalence and implications of attention-deficit hyperactivity disorder among adolescents in treatment for substance abuse. J Am Acad Child Adolesc Psychiatry 1997; 36: 30-36.
9. Kuperman S, Schlosser SS, Kramer JR, Bucholz K, Hesselbrock V, Reich T, et al. Developmental soquence from disruptive behavior diagnosis to adolescent alcohol dependence. Am J Psychiatry 2001; 158: 2022-2026.
10. Ercan ES, Coskunol H, Varan A, Toksoz K, Childhood attention deficit/ hyperactivity disorder and alcohol dependence: a 1 -year follow-up. Alcohol Alcohol 2003, 38: 352-356.
11. White AM, Jordan JD, Schroeder KM, Acheson SK Georgi BD, Sauls G, et al. Predictors of relapse during treatment and treatment completion among marijuana-dependent adolescents in an intensive outpatient substance abuse program. Subst Abus 2004; 25: 53-59.
12. Pliszka SR, Crismon ML, Hughes CW, Corners CK. Emslie GJ, Jensen PS, et al. The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45: 642-657.
13. Volkow ND, Fowler JS, Wang GJ. The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies. Neuropharmacology 2004; 47 (Suppl 1): 3-13.
14. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005: 57: 1410-1415.
15. Riggs PD, Leon SL, Mikulich SK, Pottle LC. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry 1998, 37: 1271-1278.
16. Solhkhah R, Wilens TE, Daly J, Prince JB, Van Patten SL, Biederman J. Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit/hyperactivity disorder and mood disorders. J Child Adolesc Psychopharmacol 2005: 15: 777-786.
17. Riggs PD, Hall SK, Mikulich-Gilbertson SK, Lohman M, Kayser A. A randomized controlled trial of pemoline for attention-deficit/ hyperactivity disorder in substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43: 420-429.
18. Schubiner H, Saules KK, Arfken CL, Johanson CE, Schuster CR, Lockhart N, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10: 286-294.
19. Carpentier PJ, de Jong CA, Dijkstra BA, Verbrugge CA, Krabbe PF. A controlled trial of methylphenidate in adults with attention deficit/ hyperactivity disorder and substance use disorders. Addiction 2005: 100: 1868-1874.
20. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87: 20-29.
21. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81: 137-148.
22. Kuperman S, Perry PJ, Gaffney GR, Lund BC, Bever-Stille KA, Arndt S, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry 2001; 13: 129-134.
23. Chambers RA, Taylor JR, Potenza MN, Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability. Am J Psychiatry 2003; 160: 1041-1052.
24. Stansfield KH, Kirstein CL. Neurochemical effects of cocaine in adolescence compared to adulthood. Brain Res Dev Brain Res 2005; 159: 119-125.
25. Szobot CM, Rohde LA, Bukstein O, Molina BS, Martins C, Ruaro P, et al. Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction 2007: 102: 1122-1130.
26. Liu F. Muniz R, Minami H, Silva RR. Review and comparison of the long acting methylphenidate preparations. Psychiatr Q 2005; 76: 259-269.
27. Rohde LA, Szobot C, Polanczyk G, Schmitz M, Martins S, Tramontina S. Attention-deficit/hyperactivity disorder in a diverse culture: do research and clinical findings support the notion of a cultural construct for the disorder? Biol Psychiatry 2005, 57: 1436-1441.
28. Amorim P. Mini International Neuropsychiatric Interview (MINI): Validação cle entrevista breve para diagnostico de transtornos mentais. Rev Bras Psiquiatr 2000, 22: 106-115.
29. Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry 1983; 40: 1228-1231.
30. Associaçã Brasileira de Empresas de Pesquisas. Critério de Classificação Econômica Brasil. http://www.anep.org.br/codigosguias/CCEP.pdf. Accessed April 18, 2005.
31. Wechsler D. WISC-III/Manual. New York: The Psychological Corporation: 1991.
32. Wechsler D. Manual of the Wechsler Adult Intelligence Scale. 3rd edn. San Antonio: The Psychological Corporation, 1997.
33. Swanson J. School-based assessments and Interventions for ADD students. Irvine: KC Publishing; 1992.
34. National Institute of Mental Health. CGI (Clinical Global Impression) scale. Psychopharmacol Bull 1985; 21: 839-843.
35. Barkley RA. Attention Deficit Hyperactivity Disorder: A handbook for diagnosis and treatment. New York: Guilford Press; 1990.
36. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry 2004; 61: 310-317.
37. Littell RC, Pendergast J, Natarajan R. Modelling covariance structore in the analysis of repeated measures data. Stat Med 2000, 19: 1793-1819.
38. oob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997; 278: 52-58.
39. Volkow ND, Wang GJ, Fowler JS, Telang F, Maynard L, Logan J, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry 2004; 161: 1173-1180.
40. Toga AW, Thompson PM, Sowell ER. Mapping brain maturation. Trends Neurosci 2006; 29: 148-159.